Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Revenue projections:

Johnson & Johnson's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio	1.089000
forwardPE	20.783314
debtToEquity	57.709000
earningsGrowth	-0.009000
revenueGrowth	0.066000
grossMargins	0.681400
operatingMargins	0.291900
trailingEps	8.630000
forwardEps	11.962000

With a current ratio of 1.089, JNJ has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that JNJ is in a strong position to meet its immediate financial obligations without difficulty.
JNJ's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
JNJ's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
JNJ's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
JNJ's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for JNJ's financial growth.

Price projections:

Over time, JNJ's price projections have been revised higher, signaling growing confidence in the company's future. This upward trend suggests analysts anticipate strong performance and increased market value for JNJ.

Insider Transactions:

Recent trading of JNJ stock saw 16 sales, with market price at 233.04577255249023 per share.There were 1 transactions to buy Johnson & Johnson stock, with market price of 207.55999755859375.JNJ's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

A recent buy bias from analysts toward Johnson & Johnson may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that Johnson & Johnson might be an appealing option for those looking to grow their wealth through stock market investments.